Linking Glycogen and Senescence in Cancer Cells

Total Page:16

File Type:pdf, Size:1020Kb

Linking Glycogen and Senescence in Cancer Cells Cell Metabolism Previews Linking Glycogen and Senescence in Cancer Cells Susana Ros1 and Almut Schulze1,* 1Gene Expression Analysis Laboratory, Cancer Research UK London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3LY, UK *Correspondence: [email protected] http://dx.doi.org/10.1016/j.cmet.2012.11.010 Glycogen metabolism operates as an alternative energy source, enabling cell growth under conditions of metabolic stress. Favaro et al. (2012) now demonstrate that in hypoxic cancer cells, depletion of liver glycogen phosphorylase causes glycogen accumulation, leading to oxidative stress, induction of senes- cence, and impaired tumor growth in vivo. Among the various metabolic adaptations (PYGL) was previously found among the the survival of cancer cells (Figure 1). employed by cancer cells to adjust to the 99 genes included in a hypoxia ‘‘meta- Based on this model, PYGL silencing conditions imposed by the tumor micro- gene’’ signature, which predicts poor impairs glycogen breakdown, results in environment, changes in glycogen meta- survival in head and neck squamous cell decreased flux through the PPP, and bolism are emerging as an essential carcinomas and breast cancer (Winter diminishes NADPH levels, which not only response (Brahimi-Horn et al., 2011). et al., 2007). Therefore, the role of provide the reductive power for the Understanding the role of glycogen glycogen degradation in response to synthesis of macromolecules for cell metabolism in neoplastic transformation hypoxia and in cancer cell survival re- growth and proliferation, but also main- requires a better knowledge of how this mained unclear. tain cellular redox balance. The increase metabolic pathway is regulated in cancer. To address this question, Favaro et al. in reactive oxygen species (ROS) after Favaro et al. now demonstrate that inhibi- examined xenografts of U87 glioblastoma silencing of PYGL leads to p53 activation tion of glycogen mobilization in cancer cells in mice treated with the antiangio- and induction of senescence. In agree- cells leads to the induction of senes- genic drug bevacizumab. They found ment with this conclusion, Favaro et al. cence and impairs tumor growth (Favaro that hypoxic areas in the treated tumors found that induction of senescence was et al., 2012). expressed both GYS1 and PYGL and partially reversed by cosilencing of p53 Hypoxia is an important component of showed marked accumulation of gly- or treatment with a ROS scavenger. the tumor microenvironment and regu- cogen. Consistent with this finding, they However, it cannot be excluded that the lates several processes essential for observed an acute induction of GYS1 hyperaccumulation of glycogen itself has tumor formation. Hypoxia promotes the expression and glycogen accumulation an effect on cellular signaling processes storage of glucose in the form of glycogen in several cancer cell lines (U87 glioblas- and contributes to the induction of senes- in nonmalignant as well as in cancer cells toma, MCF-7 breast cancer, and HCT- cence. Evidence for this comes from the for later use under more drastic, nutrient- 116 colon cancer cells) exposed to cosilencing of glycogen synthase, which limiting conditions (Brahimi-Horn et al., hypoxia. PYGL mRNA levels, on the other resulted in diminished glycogen stores 2011). A previous study showed that hand, increased only after longer expo- and rescued the senescence phenotype. nonmalignant cells exposed to low sure to hypoxia and correlated with Several published observations reinforce oxygen induce the expression of GYS1, a reduction in glycogen content, suggest- this concept. The b1 subunit of AMPK the muscle isoform of glycogen synthase ing activation of glycogen breakdown contains a glycogen-binding site, and (the key enzyme involved in glycogen during the later stages of the hypoxia AMPK is believed to be in its active state synthesis), using a mechanism depen- response. Indeed, PYGL expression was when glycogen particles are fully synthe- dent on the hypoxia-inducible factor elevated in several different tumor types, sized. Persistent activation of AMPK can (HIF) (Pescador et al., 2010). However, relative to normal tissues. Importantly, lead to the induction of p53-dependent the activity of glycogen phosphorylase silencing of PYGL, by siRNA, in different cellular senescence (Jones et al., 2005). (the key enzyme involved in glycogen cancer cell lines led to increased Furthermore, sublethal doses of inhibitors degradation) was decreased (Pescador glycogen content and resulted in induc- of glycogen synthase kinase 3 (GSK-3), et al., 2010). Parallel findings were re- tion of senescence, both in normoxia one of the kinases that regulates glycogen ported in human MCF-7 breast cancer and hypoxia, although the increase in synthesis through phosphorylation and cells (Shen et al., 2010). In this system, glycogen stores was more prominent in inhibition of glycogen synthase, have short-term hypoxia led to glycogen accu- low oxygen. Remarkably, PYGL silencing also been reported to induce cellular mulation by the HIF-dependent induction by shRNA strongly impaired the growth senescence accompanied by enhanced of protein phosphatase 1 regulatory of the U87 xenograft cells. glycogenesis and increased glycogen subunit 3C (PPP1R3C or PTG). This acti- To explain these findings, Favaro et al. content (Seo et al., 2008). vated glycogen synthase and decreased propose a model in which channeling of Previous studies suggested that short- glycogen phosphorylase activity (Shen glucose-6-phosphate toward the pentose term hypoxia promotes accumulation of et al., 2010). On the other hand, the liver phosphate pathway (PPP), caused by glycogen by increasing glycogen syn- isoform of glycogen phosphorylase glycogen mobilization, is essential for thase activity while decreasing the activity Cell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc. 687 Cell Metabolism Previews players involved in glycogen metabolism that can be considered as targets for future anticancer therapies. The study by Favaro et al. highlights glycogen metabolism as a promising metabolic Achilles’ heel for cancer treat- ment. Moreover, glycogen mobilization could allow cancer cells to bypass limita- tions in nutrient supply caused by antian- giogenic drugs, making it an attractive target for combination therapies. This study paves the way for a better under- standing of the regulation of this impor- tant metabolic pathway in cancer. Figure 1. Overview of Glycogen Metabolism in Cancer Cells Exposed to Hypoxia and Effects REFERENCES of PYGL Depletion Favaro et al. report the induction of several enzymes involved in glycogen synthesis (blue) and degradation 10 (red) in cancer cells under hypoxic conditions. Channeling of glucose through glycogen promotes the Agius, L. (2010). Mini Rev. Med. Chem. , 1175– survival of cancer cells under hypoxia. Depletion of PYGL reduces glycogen mobilization and impairs 1187. NADPH production due to decreased flux through the PPP, resulting in ROS accumulation and induction Brahimi-Horn, M.C., Bellot, G., and Pouysse´ gur, J. of senescence. Branching enzyme 1, GBE1; glucose transporter 1, GLUT1; glycogen phosphorylase liver (2011). Curr. Opin. Genet. Dev. 21, 67–72. isoform, PYGL; glycogen synthase muscle isoform, GYS1; glucose-1-phosphate, Glc-1-P; glucose-6- phosphate, Glc-6-P; hexokinase II, HK-II; phosphoglucomutase 1, PGM-1; pentose phosphate pathway, Camus, S., Quevedo, C., Mene´ ndez, S., Paramo- PPP; reactive oxygen species, ROS; UDP-glucose, UDP-Glc. nov, I., Stouten, P.F., Janssen, R.A., Rueb, S., He, S., Snaar-Jagalska, B.E., Laricchia-Robbio, L., and Izpisua Belmonte, J.C. (2012). Oncogene of glycogen phosphorylase (Shen et al., cancer. However, it is important to 31, 4333–4342. 2010). The results of Favaro et al. now consider that the phosphorylated (active) Favaro, E., Bensaad, K., Chong, M.G., Tennant, also implicate glycogen mobilization in form of PYGL is a potent allosteric inhib- D.A., Ferguson, D.J.P., Snell, C., Steers, G., Turley, H., Li, J.-L., Gu¨ nther, U.L., et al. (2012). Cell Metab. the late response of cancer cells to itor of protein phosphatase-1 (PP1), which 16, this issue, 751–764. hypoxia. The late induction of PYGL may dephosphorylates and activates glycogen reflect the temporally dynamic nature of synthase (Agius, 2010). PYGL inhibition Jones, K.R., Elmore, L.W., Jackson-Cook, C., Demasters, G., Povirk, L.F., Holt, S.E., and Ge- glycogen metabolism within the hypoxia could thus not only prevent glycogen wirtz, D.A. (2005). Int. J. Radiat. Biol. 81, 445–458. response. This could be particularly degradation but also promote its syn- Pelletier, J., Bellot, G., Gounon, P., Lacas-Gervais, important in the context of fluctuating thesis, thereby further limiting the flux of S., Pouysse´ gur, J., and Mazure, N.M. (2012). Front. nutrient and oxygen availability within glucose-6-phosphate toward the PPP Oncol. 2, 18. the tumor microenvironment. (Figure 1). Indeed, other proteins involved Pescador, N., Villar, D., Cifuentes, D., Garcia- These findings suggest that PYGL may in glycogen metabolism, some of them Rocha, M., Ortiz-Barahona, A., Vazquez, S., represent a target for anticancer therapy. being regulated by HIF, have been already Ordon˜ ez, A., Cuevas, Y., Saez-Morales, D., 5 Drug discovery programs are already proposed as therapeutic targets (Pelletier Garcia-Bermejo, M.L., et al. (2010). PLoS ONE , e9644. exploring PYGL as a therapeutic target et al., 2012; Pescador et al., 2010). for the treatment of type 2 diabetes,
Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • PYGL Rabbit Polyclonal Antibody
    PYGL Rabbit Polyclonal Antibody CAB6710 Product Information Protein Background Size: This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1, 4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from 20uL, 50uL, 100uL, 200uL inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal Observed MW: controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that 110kDa are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just Calculated MW: those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in 93kDa/97kDa moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms. Applications: WB IF IP Immunogen information Reactivity: Gene ID: 5836 Human, Mouse, Rat Uniprot P06737 Antibody Information Recommended dilutions: Synonyms: WB 1:500 - 1:2000 IF 1:50 - PYGL; GSD6 1:200 IP 1:50 - 1:200 Source: Rabbit Immunogen: Recombinant fusion protein containing a sequence corresponding Isotype: to amino acids 1-280 of human PYGL (NP_002854.3). IgG Storage: Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. Purification: Affinity purification Copyright © 2021 Assay Genie [email protected] www.assaygenie.com Product Images Western blot analysis of extracts of various cell lines, using PYGL antibody (CAB6710) at 1:1000 dilution.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Molecular Diagnosis of Glycogen Storage Disease and Disorders with Overlapping Clinical Symptoms by Massive Parallel Sequencing
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Molecular diagnosis of glycogen storage disease and disorders with overlapping clinical symptoms by massive parallel sequencing Ana I Vega, PhD1,2,3, Celia Medrano, BSc1,2,3, Rosa Navarrete, BSc1,2,3, Lourdes R Desviat, PhD1,2,3, Begoña Merinero, PhD1,2,3, Pilar Rodríguez-Pombo, PhD1,2,3, Isidro Vitoria, MD, PhD4, Magdalena Ugarte, PhD1,2,3, Celia Pérez-Cerdá, PhD1,2,3 and Belen Pérez, PhD1,2,3 Purpose: Glycogen storage disease (GSD) is an umbrella term for a Results: Pathogenic mutations were detected in 23 patients. group of genetic disorders that involve the abnormal metabolism of ­Twenty-two mutations were recognized (mostly loss-of-function glycogen; to date, 23 types of GSD have been identified. The nonspe- mutations), including 11 that were novel in GSD-associated genes. In cific clinical presentation of GSD and the lack of specific biomarkers addition, CES detected five patients with mutations in ALDOB, LIPA, mean that Sanger sequencing is now widely relied on for making a NKX2-5, CPT2, or ANO5. Although these genes are not involved in diagnosis. However, this gene-by-gene sequencing technique is both GSD, they are associated with overlapping phenotypic characteristics laborious and costly, which is a consequence of the number of genes such as hepatic, muscular, and cardiac dysfunction. to be sequenced and the large size of some genes. Conclusions: These results show that next-generation sequenc- ing, in combination with the detection of biochemical and clinical Methods: This work reports the use of massive parallel sequencing hallmarks, provides an accurate, high-throughput means of making to diagnose patients at our laboratory in Spain using either a cus- genetic diagnoses of GSD and related diseases.
    [Show full text]
  • Six Glycolysis-Related Genes As Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma
    Hindawi BioMed Research International Volume 2021, Article ID 8824195, 13 pages https://doi.org/10.1155/2021/8824195 Research Article Six Glycolysis-Related Genes as Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma LangXiong Chen ,1,2 XiaoSong He,1,2 ShiJiang Yi,1,2 GuanCheng Liu,1,2 Yi Liu,1,2 and YueFu Ling 1,2 1Otolaryngology & Head and Neck Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China 2The Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China Correspondence should be addressed to YueFu Ling; [email protected] Received 19 September 2020; Revised 10 January 2021; Accepted 15 January 2021; Published 10 February 2021 Academic Editor: R. K. Tripathy Copyright © 2021 LangXiong Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Head and neck squamous cell carcinoma (HNSCC) is one of the worst-prognosis malignant tumors. This study used bioinformatic analysis of the transcriptome sequencing data of HNSCC and the patients’ survival and clinical data to construct a prediction signature of glycolysis-related genes as the prognostic risk markers. Methods. Gene expression profile data about HNSCC tissues (n = 498) and normal tissues in the head and neck (n =44) were got from The Cancer Genome Atlas (TCGA), as well as patients’ survival and clinical data. Then, we obtained core genes; their expression in head and neck squamous cell carcinoma tissues is significantly different from that in normal head and neck tissues.
    [Show full text]
  • Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease
    cells Review Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease Marta Migocka-Patrzałek * and Magdalena Elias Department of Animal Developmental Biology, Faculty of Biological Sciences, University of Wroclaw, 50-335 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Glycogen phosphorylase (PG) is a key enzyme taking part in the first step of glycogenolysis. Muscle glycogen phosphorylase (PYGM) differs from other PG isoforms in expression pattern and biochemical properties. The main role of PYGM is providing sufficient energy for muscle contraction. However, it is expressed in tissues other than muscle, such as the brain, lymphoid tissues, and blood. PYGM is important not only in glycogen metabolism, but also in such diverse processes as the insulin and glucagon signaling pathway, insulin resistance, necroptosis, immune response, and phototransduction. PYGM is implicated in several pathological states, such as muscle glycogen phosphorylase deficiency (McArdle disease), schizophrenia, and cancer. Here we attempt to analyze the available data regarding the protein partners of PYGM to shed light on its possible interactions and functions. We also underline the potential for zebrafish to become a convenient and applicable model to study PYGM functions, especially because of its unique features that can complement data obtained from other approaches. Keywords: PYGM; muscle glycogen phosphorylase; functional protein partners; glycogenolysis; McArdle disease; cancer; schizophrenia Citation: Migocka-Patrzałek, M.; Elias, M. Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells 1. Introduction 2021, 10, 883. https://doi.org/ The main energy substrate in animal tissues is glucose, which is stored in the liver and 10.3390/cells10040883 muscles in the form of glycogen, a polymer consisting of glucose molecules.
    [Show full text]
  • PHKG1 (RR-34): Sc-100536
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . PHKG1 (RR-34): sc-100536 BACKGROUND PRODUCT PHKG1 (phosphorylase kinase subunit γ1), is a subunit of phosphorylase Each vial contains 100 µg IgG 2a kappa light chain in 1.0 ml of PBS with kinase (PHK) that belongs to the Ser/Thr protein kinase family. PHK is a < 0.1% sodium azide and 0.1% gelatin. hexadecameric protein composed of four α chains, four β chains, four γ chains and four δ chains. The γ chains are catalytic chains, the α and β APPLICATIONS chains are regulatory chains and the δ chains are calmodulins. PHKG1 con - PHKG1 (RR-34) is recommended for detection of PHKG1 of human origin tains two calmodulin-binding domains and one protein kinase domain. As by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), the catalytic chain of PHK, PHKG1 is responsible for catalyzing the phospho- immunohistochemistry (including paraffin-embedded sections) (starting rylation and activation of glycogen phosphorylase and therefore it plays an dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting important role in the glycogenolytic pathway. Mutations in the gene encoding dilution 1:30, dilution range 1:30-1:3000). PHKG1 can lead to PHK deficiency and result in glycogen storage disease type 9C (GSD9C), also known as autosomal liver glycogenosis. Suitable for use as control antibody for PHKG1 siRNA (h): sc-89501, PHKG1 shRNA Plasmid (h): sc-89501-SH and PHKG1 shRNA (h) Lentiviral Particles: REFERENCES sc-89501-V. 1. Hanks, S.K. 1989. Messenger ribonucleic acid encoding an apparent isoform Molecular Weight of PHKG1: 45 kDa.
    [Show full text]
  • Human Kinases Info Page
    Human Kinase Open Reading Frame Collecon Description: The Center for Cancer Systems Biology (Dana Farber Cancer Institute)- Broad Institute of Harvard and MIT Human Kinase ORF collection from Addgene consists of 559 distinct human kinases and kinase-related protein ORFs in pDONR-223 Gateway® Entry vectors. All clones are clonal isolates and have been end-read sequenced to confirm identity. Kinase ORFs were assembled from a number of sources; 56% were isolated as single cloned isolates from the ORFeome 5.1 collection (horfdb.dfci.harvard.edu); 31% were cloned from normal human tissue RNA (Ambion) by reverse transcription and subsequent PCR amplification adding Gateway® sequences; 11% were cloned into Entry vectors from templates provided by the Harvard Institute of Proteomics (HIP); 2% additional kinases were cloned into Entry vectors from templates obtained from collaborating laboratories. All ORFs are open (stop codons removed) except for 5 (MST1R, PTK7, JAK3, AXL, TIE1) which are closed (have stop codons). Detailed information can be found at: www.addgene.org/human_kinases Handling and Storage: Store glycerol stocks at -80oC and minimize freeze-thaw cycles. To access a plasmid, keep the plate on dry ice to prevent thawing. Using a sterile pipette tip, puncture the seal above an individual well and spread a portion of the glycerol stock onto an agar plate. To patch the hole, use sterile tape or a portion of a fresh aluminum seal. Note: These plasmid constructs are being distributed to non-profit institutions for the purpose of basic
    [Show full text]
  • Mutations in PHKA1, PHKG1 Or Six Other Candidate Genes Explain Only a Minority of Cases
    European Journal of Human Genetics (2003) 11, 516–526 & 2003 Nature Publishing Group All rights reserved 1018-4813/03 $25.00 www.nature.com/ejhg ARTICLE Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases Barbara Burwinkel1,7, Bin Hu1, Anja Schroers2, Paula R. Clemens3,8, Shimon W. Moses4, Yoon S. Shin5, Dieter Pongratz6, Matthias Vorgerd2 and Manfred W. Kilimann*,1,9 1Institut fu¨r Physiologische Chemie, Ruhr-Universita¨t Bochum, D-44780 Bochum, Germany; 2Neurologische Universita¨tsklinik Bergmannsheil, Ruhr-Universita¨t Bochum, Bu¨rkle-de-la-Camp-Platz 1, D-44789 Bochum, Germany; 3Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA; 4Department of Pediatrics, Soroka Medical Center, Ben Gurion University of the Negev, IL-84105 Beer-Sheva, Israel; 5Stoffwechselzentrum, Dr V Haunersches Kinderspital der Universita¨t Mu¨nchen, D-80337 Mu¨nchen, Germany; 6Friedrich-Baur-Institut der Universita¨t Mu¨nchen, Ziemssenstr. 1, D-80336 Mu¨nchen, Germany Muscle-specific deficiency of phosphorylase kinase (Phk) causes glycogen storage disease, clinically manifesting in exercise intolerance with early fatiguability, pain, cramps and occasionally myoglobinuria. In two patients and in a mouse mutant with muscle Phk deficiency, mutations were previously found in the muscle isoform of the Phk a subunit, encoded by the X-chromosomal PHKA1 gene (MIM # 311870). No mutations have been identified in the muscle isoform of the Phk c subunit (PHKG1). In the present study, we determined the structure of the PHKG1 gene and characterized its relationship to several pseudogenes. In six patients with adult- or juvenile-onset muscle glycogenosis and low Phk activity, we then searched for mutations in eight candidate genes.
    [Show full text]
  • Inhibition of ERK 1/2 Kinases Prevents Tendon Matrix Breakdown Ulrich Blache1,2,3, Stefania L
    www.nature.com/scientificreports OPEN Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown Ulrich Blache1,2,3, Stefania L. Wunderli1,2,3, Amro A. Hussien1,2, Tino Stauber1,2, Gabriel Flückiger1,2, Maja Bollhalder1,2, Barbara Niederöst1,2, Sandro F. Fucentese1 & Jess G. Snedeker1,2* Tendon extracellular matrix (ECM) mechanical unloading results in tissue degradation and breakdown, with niche-dependent cellular stress directing proteolytic degradation of tendon. Here, we show that the extracellular-signal regulated kinase (ERK) pathway is central in tendon degradation of load-deprived tissue explants. We show that ERK 1/2 are highly phosphorylated in mechanically unloaded tendon fascicles in a vascular niche-dependent manner. Pharmacological inhibition of ERK 1/2 abolishes the induction of ECM catabolic gene expression (MMPs) and fully prevents loss of mechanical properties. Moreover, ERK 1/2 inhibition in unloaded tendon fascicles suppresses features of pathological tissue remodeling such as collagen type 3 matrix switch and the induction of the pro-fbrotic cytokine interleukin 11. This work demonstrates ERK signaling as a central checkpoint to trigger tendon matrix degradation and remodeling using load-deprived tissue explants. Tendon is a musculoskeletal tissue that transmits muscle force to bone. To accomplish its biomechanical function, tendon tissues adopt a specialized extracellular matrix (ECM) structure1. Te load-bearing tendon compart- ment consists of highly aligned collagen-rich fascicles that are interspersed with tendon stromal cells. Tendon is a mechanosensitive tissue whereby physiological mechanical loading is vital for maintaining tendon archi- tecture and homeostasis2. Mechanical unloading of the tissue, for instance following tendon rupture or more localized micro trauma, leads to proteolytic breakdown of the tissue with severe deterioration of both structural and mechanical properties3–5.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ~ClariCELL™ ~ Targets P.18 Detection of Protein-Protein Interactions ~ProbeX™~ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ~Premium~ P.20-21 FastLane™ Structures ~Standard~ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1~3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]
  • Extracellular Vesicles Released By
    Published OnlineFirst October 25, 2017; DOI: 10.1158/1078-0432.CCR-17-2046 Cancer Therapy: Preclinical Clinical Cancer Research Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury Chontida Yarana1,2, Dustin Carroll1, Jing Chen3, Luksana Chaiswing1, Yanming Zhao1, Teresa Noel1, Michael Alstott4, Younsoo Bae5, Emily V. Dressler6, Jeffrey A. Moscow7, D. Allan Butterfield4,8, Haining Zhu1,3,4, and Daret K. St. Clair1 Abstract Purpose: Cardiac injury is a major cause of death in cancer tinctive presence of brain/heart, muscle, and liver isoforms of survivors, and biomarkers for it are detectable only after tissue glycogen phosphorylase (GP), and their origins were verified to injury has occurred. Extracellular vesicles (EV) remove toxic be heart, skeletal muscle, and liver, respectively. The presence of biomolecules from tissues and can be detected in the blood. brain/heart GP (PYGB) in DOX_EVs correlated with a reduction of Here, we evaluate the potential of using circulating EVs as early PYGB in heart, but not brain tissues. Manganese superoxide dis- diagnostic markers for long-term cardiac injury. mutase (MnSOD) overexpression, as well as pretreatment with Experimental Design: Using a mouse model of doxorubicin cardioprotective agents and MnSOD mimetics, resulted in a reduc- (DOX)-induced cardiac injury, we quantified serum EVs, analyzed tion of EV-associated PYGB in mice treated with DOX. Kinetic proteomes, measured oxidized protein levels in serum EVs released studies indicated that EVs containing PYGB were released prior to after DOX treatment, and investigated the alteration of EV content. the rise of cardiac troponin in the blood after DOX treatment, Results: Treatment with DOX caused a significant increase in suggesting that PYGB is an early indicator of cardiac injury.
    [Show full text]